11-20-01

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
twork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REVIVAL OF AN APPLICATION FOR PATENT ABANDONED **UNINTENTIONALLY UNDER 37 CFR 1.137(b**

Docket Number (Optional)

Cell 4.20 CIP2

First named inventor: Jakobovits, et al.					
Application No.: 09/187,693		Group Art Unit:	1644		
Filed:	November 5, 1	998	Examiner: Saoud, C) .	
Title: Human Monoclonal Antibodies to Epidermal Growth Factor Receptor					
Assistant Commissioner for Patents Box DAC Washington, D.C. 20231					
NOTE:	NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.				
The above-identified application because abandoned for failure to file a timely and proper reply to a notice or action by the Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.					
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION					
NOTE: A grantable petition requires the following items: (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal Disclaimer with disclaimer fee – required for all utility and plant applications filed before June 8, 1995; and (4) Statement that the entire delay was unintentional/					
1. Petition fee ¹☐ Small entity – fee \$(37 CFR 1.17(m))				RECEIVED	
	Small entity – fee \$(37 CFR 1.17(III)) Small entity statement enclosed herewith. Small entity statement previously filed. Other than small entity – fee \$(37 CFR 1.17(m))			NOV 2 1 2000	
2. Reply and/or fee				OFFICE OF PETITIONS	
A. The reply and/or fee to the above noted Office action in the form of Preliminary Amendment and Sequence Listing (identify type of reply):					
	has been file is enclosed	ed previously on herewith.			
B. The issue fee of \$ has been paid previously on					
	is enclosed				
 Terminal disclaimer with disclaimer fee Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required. A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming a period equivalent to the period of abandonment is enclosed herewith (see PTO/SB/63). 					
4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.					
11/17/2000 (Cliption)					
Date Abgenix, Inc. 7601 Dumbarton Circle Fremont, CA 94555 Christopher A. Hare, Reg. No. 37,637					
CERTIFICATE OF EXPRESS MAILING					
I hereby certify that this correspondence is, on the date shown below, being deposited with the United States Postal Service via "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231					
Date: 1/-17-00 Signature: Watura M. Suras					
Express Mail Label No.:					

11/21/2000 SDUDNG

09187693 00000060 010038

01 FC:141

1240.00 OP